InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Stock Information for InMed Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About InMed Pharmaceuticals Inc.

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
InMed Announces Results of 2023 Annual General Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.